Vanda Pharmaceuticals Inc.
News and overview for Vanda Pharmaceuticals Inc.
Vanda licenses schizophrenia drug to Novartis - MarketWatch
MarketWatch | 42 days 16 hours 28 minutes ago
Vanda licenses schizophrenia drug to Novartis
Vanda Pharmaceuticals announces financial results for the third quarter of 2009
News-Medical.Net | 22 days 11 hours 10 minutes ago
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2009.
Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG
News-Medical.Net | 41 days 17 hours 9 minutes ago
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults. Fanapt((TM)) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist. The U.S. anti-psychotic market is approximately $14 billion.
Vanda Pharmaceuticals announces its agreement to commercialize and develop Fanapt
News-Medical.Net | 42 days 19 hours 1 minute ago
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults. Fanapt((TM)) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist. The U.S. anti-psychotic market is approximately $14 billion.
Vanda Pharmaceuticals Reports Third Quarter 2009 Results [Press Release]
PRNewswire | 22 days 6 hours 28 minutes ago
ROCKVILLE, Md., Nov. 2 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda)
Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma
News-Medical.Net | 42 days 18 hours 11 minutes ago
Titan Pharmaceuticals, Inc (Pink Sheets:TTNP) today announced that Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) reported its entry into an exclusive agreement with Novartis Pharma AG to commercialize and develop Fanaptâ?¢ (iloperidone) in the U.S. and Canada. Fanaptâ?¢, an atypical anti-psychotic, was approved by the U.S. Food and Drug Administration earlier this summer for the acute treatment of schizophrenia in adults. The U.S. anti-psychotic market is approximately $14 billion a year.
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia [Press Release]
PRNewswire | 42 days 21 hours 28 minutes ago
...PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. announced today that it...www.fanapt.com Vanda Pharmaceuticals Inc. is a biopharmaceutical...assumptions and uncertainties. Vanda Pharmaceuticals Inc. is at an early stage of...
Vanda Pharmaceuticals Reports Second Quarter 2009 Results [Press Release]
PRNewswire | 106 days 13 hours 57 minutes ago
ROCKVILLE, Md., Aug. 10 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda)
Vanda shares rise after signs deal with Novartis
Forbes | 42 days 8 hours 37 minutes ago
* Vanda's shares rise 7.3 percent after Novartis deal * Novartis ( NVS - news - people ) to pay Vanda $200 mln for U.S. rights to Fanapt
Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009 [Press Release]
PRNewswire | 26 days 20 hours 28 minutes ago
...Oct. 28 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) , a biopharmaceutical company focused on...callers. The access number is 87052099. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on...
Novartis Pharma Acquires Exclusive Rights From Vanda Pharmaceuticals for Commercialization of Fanapt in the United States and Canada [Press Release]
Business Wire | 42 days 21 hours 36 minutes ago
Titan Pharmaceuticals, Inc (Pink Sheets:TTNP) today announced that Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) reported its entry into an exclusive agreement with Novartis Pharma AG to commercialize and develop Fanapt™ (iloperidone) in the U.S. and Canada. Fanapt™, an atypical anti-psychotic, was approved by the U.S. Food and Drug Administration earlier this summer for the acute treatment of schizophrenia in adults. The U.S. anti-psychotic market is approximately $14 billion a year.
Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 [Press Release]
PRNewswire | 110 days 3 hours 54 minutes ago
...Aug. 6 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) , a biopharmaceutical company focused on...callers. The access number is 78449791. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on...
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia [Press Release]
PRNewswire | 42 days 21 hours 27 minutes ago
...Rights to Fanapt acquired from Vanda Pharmaceuticals Inc. for upfront payment of USD 200 million; Vanda eligible for milestones and...part of the agreement with Vanda Pharmaceuticals Inc., Novartis will have exclusive...
Tuesday's biggest gaining and declining stocks - MarketWatch
MarketWatch | 42 days 12 hours 40 minutes ago
Toolmaker Black & Decker issued a stunning earnings outlook Monday, but much of its boost comes from a tax break. It seems the one thing that everyone needs, sales growth, still proves elusive.
Drug stocks slip; J&J falls on earnings report - MarketWatch
MarketWatch | 42 days 9 hours 46 minutes ago
Shares of J&J /quotes/comstock/13*!jnj/quotes/nls/jnj (JNJ 60.83, -1.70, -2.71%) were down almost 3% at $60.87.
Company Overview
| Company: | Vanda Pharmaceuticals Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.vandapharma.com |
Vanda wants to gain an advantage in the field of neurological medicine. Vanda Pharmaceuticals is a pharmaceutical company that is developing several drugs for disorders of the central nervous system. The company's lead drug candidate, schizophrenia and bipolar disorder treatment Fanapt (formerly Fiapta, or iloperidone), received FDA approval in 2009. Other drug candidates are treatments for sleep disorders, including insomnia and sleep apnea, and depression. Vanda typically licenses development and commercialization rights for its compounds from companies including Bristol-Myers Squibb and Novartis.
Key Numbers
| Sales in U.S. Dollars (mil.) | 0 (2008) |
|---|---|
| One-year % Growth in Sales | 0.0 (2008) |
| Net Income in U.S. Dollars (mil.) | -51.1 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 24 (2008) |
| One-year % Growth in Number of Employees | -52.0 (2008) |
| Fiscal Year-End | December |